1415 related articles for article (PubMed ID: 17627161)
1. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
2. High-grade prostate cancer is associated with low serum testosterone levels.
Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
[TBL] [Abstract][Full Text] [Related]
3. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
4. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171
[TBL] [Abstract][Full Text] [Related]
5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
6. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
7. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
[TBL] [Abstract][Full Text] [Related]
8. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
[TBL] [Abstract][Full Text] [Related]
9. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
[TBL] [Abstract][Full Text] [Related]
10. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
Mo ZN; Huang X; Zhang SC; Yang JR
J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
[TBL] [Abstract][Full Text] [Related]
11. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
12. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
Laguna Pes MP; Guinda Sevillano C; Zazo Romojaro A; Domínguez J; García Luzón A; Borrego Hernando J; Gimeno Collado A
Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
[TBL] [Abstract][Full Text] [Related]
16. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
[TBL] [Abstract][Full Text] [Related]
17. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
18. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
20. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
